Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 GeneticVariation disease BEFREE Whole-exome sequencing of the primary HER2-negative breast cancer and its HER2-negative synchronous liver metastasis from a 46-year-old female revealed the presence of an activating and clonal HER3 G284R mutation. 25953157 2015
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE When treating hormone receptor-positive/HER2-negative MBC patients with endocrine therapy, it is important to differentiate patients with lung metastases from those with liver metastases. 31373147 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Univariate analysis revealed that platelet-derived growth factor AA (PDGFAA) in DV blood (dPDGFAA) (<i>P</i> = 0.001), PDGFAA in PV blood (pPDGFAA) (<i>P</i> = 0.007), and human epidermal growth factor receptor-2 in PV blood (pHER2) (<i>P</i> = 0.001), pMMP7 (<i>P</i> = 0.028), pRANTES (<i>P</i> = 0.013), and pEGF (<i>P</i> = 0.007) were significantly correlated with synchronous liver metastasis. 28275303 2017
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Therefore, trastuzumab may be an effective agent in the chemotherapeutic treatment of liver metastases in patients with HER2-positive gastric adenocarcinoma. 25526216 2014
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE There were no significant differences in the serum p105 levels among 11 patients with c-erbB-2-overexpressing carcinomas, 118 patients with c-erbB-2 non-overexpressing carcinomas and 28 controls, although a single case of gastric carcinoma overexpressing c-erbB-2 with extensive liver metastasis had a higher level than the cut-off value. 11948459 2002
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE The tissue samples of primary CRC tumors (n = 98), noninvolved colorectal mucosa (n = 98), paired lymph nodes (n = 98, 69 patients had positive metastatic nodes), and liver metastases (n = 22) were evaluated using immunohistochemistry for HER2. 30203148 2018
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 AlteredExpression disease BEFREE The expression of c-erbB-2 protein in colorectal cancer tissue correlates closely with liver metastasis but not with lymphatic or lung metastases. 11032920 2000
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE The HER2 positivity was 37.2 % (35/94) in GCLM patients and 21 % (61/290) in the overall GC patients. 27324991 2017
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Patients with a HER2-/HoR+ status had more bone metastasis, whereas patients with a HER2+/HoR- status had an increased incidence of liver metastasis. 28345619 2017
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 GeneticVariation disease BEFREE One of these patients with human epidermal growth factor receptor 2 mutation recurred early with liver metastasis. 24803549 2014
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE On binary regression analysis, hyperattenuation of the tumor (odds ratio [OR], 4.68; <i>p</i> < 0.001) and hepatic metastasis (OR, 4.43; <i>p</i> = 0.001) were significant independent factors that predict HER2-positive cancers. 28860898 2017
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Multiple logistic regression analysis identified intestinal type, absence of peritoneal metastasis, and hepatic metastasis as significant independent factors related to HER2 positivity. 26265390 2016
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 AlteredExpression disease BEFREE Moreover, c-erbB-2 mRNA predicted the development of liver metastases in tumours that had not metastasised to lymph nodes (p = 0.002). 9137444 1997
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Lung and brain metastases were common in hormone receptor-/human epidermal growth factor receptor 2+ and hormone receptor-/human epidermal growth factor receptor 2- subtypes, and patients with hormone receptor+/ human epidermal growth factor receptor 2+ and hormone receptor-/human epidermal growth factor receptor 2+ subtypes were more prone to liver metastases. 28653887 2017
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE In multivariate analysis, only subtype (ER+/HER2+ vs. ER-/HER2-; HR = 0.77; P = 0.02) and liver metastases (HR = 1.36; P = 0.01) were prognostic for survival. 31035019 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE In another patient, the HER-2 gene was amplified in the primary tumor but not in the liver metastasis. 15786420 2005
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE HR+/HER2+ had higher odds of liver metastases. 27975154 2017
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 AlteredExpression disease BEFREE Furthermore, breast cancer patients with hepatic metastasis and those with elevated s-erbB-2 serum levels above 40 U/ml had limited response to hormone or chemotherapy. 12065844 2002
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Further studies are needed to improve the prognosis of HER2 positive patients with liver metastasis or poor PS. 29168107 2018
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE For distant metastases, the results showed that there was a high probability of bone metastasis in HR-positive groups, brain and liver metastasis in HER2-positive groups, and lung metastasis in the TN group. 28472761 2017
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Complete pathologic response of HER2-positive breast cancer liver metastasis with dual anti-HER2 antagonism. 24708527 2014
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Compared with metastatic FBC, metastatic MBC patients had a higher proportion of ⩾60 years old, central portion of the breast, surgery, simultaneous bone and lung metastasis, while the proportion of Her2+/HR-, triple negative, liver metastasis only, and simultaneous bone and liver metastasis was lower. 31798694 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE C-erbB-2 was found more often in advanced cancers (P < 0.05), papillary adenocarcinoma (P < 0.01), nonscirrhous cancer (P < 0.05), and cancers with liver metastasis (P < 0.01). 8397058 1993
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 AlteredExpression disease BEFREE Based on the Her2/neu-scoring system, moderate to strong SSTR2A expression was observed in 121 of 156 (78%) liver metastases. 28213807 2017
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE A 42-year-old woman with HER2-positive salivary duct carcinoma of the parotid gland with bone and liver metastases had CR with TPH and remains in remission on maintenance trastuzumab and pertuzumab. 30478962 2018